Bacterial infections remain the leading killer worldwide which is worsened by the continuous 27 emergence of antibiotic resistance. In particular, antibiotic-resistant Enterobacteriaceae is 28 prevalent and extremely difficult to treat. Reusing existing drugs and rejuvenating the 29 therapeutic potential of existing antibiotics represent an attractive novel strategy. 30 Azidothymidine (AZT) is an antiretroviral drug which is used in combination with other 31 antivirals to prevent and to treat HIV/AIDS. AZT is also active against Gram-negative 32 bacteria but has not been developed for that purpose. Here we investigated in vitro and in 33 vivo efficacy of AZT in combination with colistin against antibiotic-resistant 34
INTRODUCTION 51
Bacterial infection remains a leading killer worldwide (1) and antibiotic resistance continues 52 to plague the effective control of this pandemic health problem (2, 3). In particular, there is 53 an urgent global threat with an increasing prevalence of multidrug-resistant 54
Enterobacteriaceae, especially carbapenem-resistant Enterobacteriaceae (CRE) such as 55
New Delhi Metallo-beta-lactamase-1 (NMD) carriers (4-8) which are extremely resistant to 56 almost all of our antibiotics (3, 9). As a result, our ability to treat serious community and 57 nosocomial acquired infections is rapidly diminishing (10). Unfortunately, the number of new 58 antibiotics reaching the market annually is unable to keep up with the development of 59 bacterial antibiotic resistance (11) (12) (13) (14) . The drug discovery process itself is arduous and 60 costly and it is almost impossible to produce a large group of effective antibiotics within a 61 short period of time to combat antibiotic resistance. Therefore, a different therapeutic 62 approach is needed to replenish our antibiotic reservoir against resistant bacteria and the 63 most promising of such strategies is to reuse existing drugs and to restore the therapeutic 64 potencies of existing antibiotics (15, 16) . 65
Azidothymidine (3 ' -azido-3'-deoxythymidine AZT) is an antiretroviral drug which is used in 66 combination with other antivirals to prevent and to treat HIV/AIDS. It inhibits viral reverse 67 transcriptase and was the first effective treatment for HIV/AIDS (17) entering the US market 68 in 1986. AZT is also active against Gram-negative bacteria (18-22) but has not been 69 developed or approved for that purpose. It is thought to inhibit bacterial DNA replication by 70 chain termination. Resistance to AZT occurs in bacteria and has been attributed to two 71 mechanisms, one of which is unknown and the other is a deficiency of thymidine kinase 72 which phosphorylates inactive AZT into the active triphosphate form (23) . 73
The rapid emergence of CRE which are often resistant to many other antibiotics, has left 74 the world with colistin as the last resort treatment option. The use of colistin has led to high 75 on November 1, 2018 by guest http://aac.asm.org/ Downloaded from serially diluted in a two-fold manner. The two drugs were mixed in a 96 well plate followed 125 by addition of a standard bacterial suspension at 1-5 x 10 5 CFU/mL in CA-MHB. After 126 incubation for 16 -20 hours at 37°C, the OD values were read using the ELx800 127 absorbance microplate reader (BioTek). The combinatory effects were determined by 128 calculating the fractional inhibitory concentration index (FICI) of the combination as follows: 129 (MIC of Drug A, tested in combination) / (MIC of Drug A, tested alone) + (MIC of Drug B, 130 tested in combination) / (MIC of Drug B, tested alone). Synergy was defined as a FICI ≤0.5, 131 no interaction was identified with an FICI >0.5 but <4 and antagonism if the FICI was >4 132
(37). 133
Time-Kill analysis of antibiotics alone and in combination with AZT against log-phase 134 bacteria. A range of different concentrations of colistin and AZT was chosen according to 135 the checkerboard evaluation as a synergistic combination. The drugs was prepared in a 136 two-fold serial dilution and was added in combination or alone to log phase bacterial 137 cultures suspension containing 1 x 10 7 CFU/mL (38) in CA-MHB, and incubated at 37°C. 138
Viability expressed as log CFU/mL was determined at 0, 2, 4, 8, 24 and 48 hours of 139 incubation by plating out 100 µL of serial dilutions of the cultures onto tryptone soy agar 140 (Oxoid) plates. The colonies on the agar plates were counted using an aCOLyte colony 141 counter (Synbiosis) and analysed with the counter's software. Synergistic activity was 142 confirmed as a≥2-log 10 decrease in CFU counts at 24 hours of the combination compared 143 to the antibiotic alone, in addition to a ≥2-log 10 decrease compared to the zero hour count 144 (Table S1 ). After 30 minutes of infection, AZT (2, 5 or 10 mg/kg) and CMS (10, 20 or 152 30 mg/kg) singly or in combination was injected intravenously into the mice. A group of 153 mice was treated with saline as a control group. At 30 minutes after infection (treatment 154 starting), 2 and 6 hours after treatment, 4 mice in each group were sacrificed and 1 ml 155 sterile PBS was injected intraperitoneally followed by gently massaging of the abdomen. 156
Peritoneal fluid was sampled aseptically. The fluid was diluted in a serial of 10-fold dilutions 157 and 100 µl of each dilution were plated onto tryptone soy agar (Oxoid) plates. Viability was 158 defined as Log CFU/ml of peritoneal fluid. 159
The animal husbandry guidelines and all animal experiments were performed according to 160 The MICs for the antibiotics and AZT were also determined against the 54 antibiotic-177 resistant isolates, E. coli and K. pneumoniae. As shown in Table 2 and Table S3 , these 178 strains were resistant to monobactam, penicillins and cephalosporins but were susceptible 179 to carbapenems. Resistance was seen for gentamicin, ciprofloxacin and trimethoprim. 90% 180 of the strains were susceptible to tigecycline and colistin. The MIC for AZT ranged from 181 0.25 to 64 for E. coli and 2 to 32 for K. pneumoniae. The 54 multidrug-resistant E. coli and 182 K. pneumoniae were tested for ESBL production using commercial ESBL-testing systems 183 and demonstrated that these were ESBL producing strains (Table S3) . 184
For colistin resistant strains, the MIC for AZT ranged from 8 to 64 with MIC50 at 8 mg/L and 185 MIC90 at 64 mg/L. The range of MIC for colistin was 2 to 8 mg/L with MIC50 at 4 mg/L and 186
MIC90 at 8 mg/L. 187
Checkerboard analysis of combination effects. The effects of combining AZT with 188 colistin were determined using checkerboard assays against all the 74 strains. As shown in 189 Table 3 As shown in Figure 2 , for the mcr-1 E. coli strain Af40 (Table S1 ), colistin at 8 mg/L (MIC) 212 inhibited bacterial growth and at 4 mg/L showed the similar growth pattern as the control. 213 AZT at 4, 2 and 1 mg/L reduced the initial counts till 4 hours and regrowth was seen. When 214 colistin at 8 mg/L was combined with the concentrations of 4, 2 and 1 mg/L AZT, kill to the 215 limit of detection was seen at 8 hours (Figure 2A -2C) . The same effects were seen when 216 colistin at 4 mg/L was combined with 4 mg/L of AZT ( Figure 2D ). Reduced effects were 217 seen when colistin at 4 mg/L with 4 and 2 mg/L of AZT and kill to the limit of detection was 218
shown at 24 hours ( Figure 2E and 2F) . range study of the two drugs was performed. For AZT, the minimal dosages (5 mg/kg) was 225 chosen which only inhibited bacterial growth but provide significant enhanced activities 226 when combined with CMS. For CMS, we found that 10 to 30 mg/kg showed no activities 227 against the infected bacteria. Therefore, for the colistin sensitive NDM-1 strain, we used 10 228 mg/kg of CMS and for the mcr-1 E. coli, we used 20 mg/kg of CMS. The drugs were tested 229 singly or in combination against the NDM-1 K. pneumoniae BAA2472 and the mcr-1 E. coli 230 strain Af40 (Table S4) . 231
As shown in Figure 3A , for strain K. pneumoniae BAA2472, compared with the untreated 232 control, colistin at 10 mg/kg showed no activities at both 2 and 6 hours and AZT at 5 mg/kg 233 inhibited bacterial growth. Combination of colistin with AZT, although only showing inhibition 234 at 2 hours, exhibited 2.72 log kill of the bacterium at 6 hours. The difference of the bacterial 235 numbers between zero hour and 6 hours was significant (P <0.001, n=4). For E. coli strain 236 Af40 ( Figure 3B ), colistin at 20 mg/kg showed the same growth pattern as the control and 237 AZT inhibited bacterial growth. Combination of colistin with AZT exhibited 1.32 and 2.96 238 log kill of the bacterium at 2 and 6 hours, respectively. The difference of the bacterial 239 numbers between zero hour and 2 hours or 6 hours was significant (P <0.01 and 0.001, 240 respectively, n=4). In both untreated control groups and the colistin treated group, all 241 animals developed mild clinical signs such as transiently hunched posture at 6 hours after 242 infection. The animals in other treatment groups showed no discomfort with normal and 243 heathy behaviors. All animals were sacrificed at 6 hours after treatment according to the 244 restriction of adverse effects in the project licence. Enterobacteriaceae (8). There is increasing evidence to show that colistin resistance is on 264 the rise, especially the discovery of plasmid born colistin resistance worldwide (26, 47, 48) . 265
It is critically important to preserve and prolong the life of the last resort of antibiotic by 266 enhanced combination therapy. Here we have shown that in combination with AZT, colistin 267 MIC was significantly reduced, especially against mcr-1 containing colistin resistant strains. 268
The enhanced activity of colistin in combination with AZT was confirmed with time kill 269 assays which provided dynamic measures of bactericidal activities of the combination over 270 time. In colistin mono exposure, complete eradication of the NDM-1 K. pneumoniae 271 BAA2472 or mcr-1 E. coli Af40 strains required much higher concentrations of the drug 272 (data not shown), however, more than 4 to 16-fold lower concentrations of colistin when 273 combined with AZT achieved the same effect. This is significant as enhancement of colistin 274 on November 1, 2018 by guest http://aac.asm.org/ Downloaded from combination with AZT will likely reduce the dose of colistin but retain maximal therapeutic 275 efficacy hence minimize its toxic profile. These data suggest that further clinical 276 development of a colistin plus AZT combination may be able to achieve an effective lower 277 dose colistin therapy against colistin-sensitive and colistin-resistant infections. 278
Bacterial infections caused by carbapenem resistant strains are life threatening and 279 effective treatment is difficult to achieve. The last resort treatment option is to use colistin 280 (9, 49). Previous studies have shown that in bacteria AZT needs to be converted to the 281 nucleotide to inhibit bacterial DNA replication (50) and that bacterial thymidine kinase is 282 responsible for the initiation of the activation process -phosphorylation of AZT (23, 50) . 283
Other antibiotics such as ciprofloxacin also inhibit DNA replication by blocking GyrA. But 284 comparison of the resistance profiles of ciprofloxacin and AZT are very different (see Table  285 3). This suggests that AZT has a different mechanism of action to other antibacterial agents 286 which are in the market. Rather, AZT is likely to act on a new target in bacteria. Further 287 studies on how AZT acts against Gram-negative bacteria are underway in our laboratories 288 by analysis of AZT mutants with next-generation sequencing and investigation of the AZT 289 effect on bacteria by performing Bacterial Cytological Profiling (BCP). 290
The therapeutic effectiveness of AZT and colistin combinations was also examined using a 291 mouse peritoneal infection model. As a potential therapeutic agent, AZT has been used to 292 treat HIV. Its bactericidal activity has been reported in vivo (19). Here we demonstrate that 293 AZT at 5 mg/kg inhibited the NDM-1 K. pneumoniae BAA2472 and the mcr-1 E. coli strain 294
Af40 growth in the mouse peritoneal infection. However, the combination of AZT with 295 colistin improved the therapeutic activities of each single agent with significant kill of the 296 bacteria at 2 or 6 hours in mouse peritoneal cavity. Most importantly, when colistin 297 methanesulfonate was completely ineffective up to 6 hours of treatment, the addition of 298 AZT was able to significantly reduce bacterial counts and attenuate the clinical signs in the 299 on November 1, 2018 by guest http://aac.asm.org/ Downloaded from animals. Here we used colistin methanesulfonate instead of colistin sulfate. The reason 300 was that colistin methanesulfonate is used clinically and is less toxic than colistin sulfate in 301 mice (51). Colistin methanesulfonate is a prodrug which needs to convert to the active form 302 of colistin (52). The conversion normally delays the activity of the drug (52). Here we 303 demonstrated that with the addition of AZT, the effect of colistin methanesulfonate and AZT 304 was significantly increased. Collectively, the data show that the application of AZT and 305 CMS combination therapy in vivo offers the potential to increase both colistin and AZT 306 activities against antibiotic-resistant Enterobacteriaceae. 307
In conclusion, in this proof-of-principle study, we demonstrated the high therapeutic efficacy 308 of AZT-plus-colistin combination therapy against antibiotic-resistant Enterobacteriaceae, 309
including mcr-1, NDM-1 and ESBL strains. ESBL strains were confirmed using 310 commercially-accepted phenotypical methods currently using in clinical practice. The 311 interaction between the genotypic characteristics of ESBL strains and this novel 312 combination therapy deserves further investigation. Importantly, we showed that the 313 combination of AZT with colistin significantly reduced the bacterial burden in vivo. This 314 early groundwork lays the foundation for further validation in clinical trials enabling 315 translation of the combination therapy into clinical benefits for patients. 316
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